Generic Name

Tafluprost

---

Classification

FDA Approved Indications

• Ocular hypertension
• Open-angle glaucoma

Mechanism of Action

Tafluprost is a prostaglandin F2α analog that reduces intraocular pressure by increasing outflow of aqueous humor through the uveoscleral pathway.

Dosage and Administration

Adult: 1 drop in the affected eye(s) once daily in the evening.

Pediatric: Safety and efficacy not established in pediatric patients.

Geriatric: No specific dosage adjustment recommended; use with caution as with other glaucoma medications.

Renal Impairment: No specific dosage adjustment needed.

Hepatic Impairment: No data available; use with caution.

Pharmacokinetics

Absorption: Rapidly absorbed through the cornea after ocular administration.

Distribution: Primarily binds to plasma proteins; ocular tissue distribution not well characterized.

Metabolism: Metabolized locally within the eye; minimal systemic metabolism.

Excretion: Systemic excretion details are limited due to minimal systemic absorption.

Half Life: Approximately 30 minutes to 1 hour systemically, but effects on intraocular pressure last longer due to topical action.

Contraindications

• Hypersensitivity to tafluprost or any component of the formulation.

Precautions

• Use with caution in patients with active ocular inflammation, corneal abnormalities, or history of herpetic keratitis.
• Monitor for eyelash growth, iris pigmentation changes, and hyperpigmentation of the eyelid.

Adverse Reactions - Common

• Conjunctival hyperemia (Common)
• Forking of eyelashes (Common)
• Foreign body sensation (Common)

Adverse Reactions - Serious

• Uveitis or eye inflammation (Rare)
• Changes in iris color (increased pigmentation) (Rare)
• Eyelash abnormalities (Rare)

Drug-Drug Interactions

N/A

Drug-Food Interactions

N/A

Drug-Herb Interactions

N/A

Nursing Implications

Patient/Family Teaching

• Use the medication exactly as prescribed, once daily in the evening.
• Report any eye redness, pain, or vision changes promptly.
• Be aware that iris pigmentation may increase with long-term use.
• Wash hands before applying drops and avoid touching the dropper tip to eye or other surfaces.

Special Considerations

Black Box Warnings:

• No black box warnings for tafluprost.

Genetic Factors: Significant iris pigmentation changes may be more noticeable in individuals with different baseline iris colors.

Lab Test Interference: Changes in iris color are the primary observable laboratory change.

Overdose Management

Signs/Symptoms: Overdose is unlikely but may result in ocular irritation or systemic effects, such as respiratory issues.

Treatment: Remove excess medication, rinse eye with water, and seek medical advice if symptoms persist or if systemic symptoms occur.

Storage and Handling

Storage: Store unopened bottles in a refrigerator (2°C to 8°C) and protect from light. Once opened, bottle may be stored at room temperature up to 25°C for up to 6 weeks.

Stability: Stable for 6 weeks after opening when stored properly.